The assessment of measurable residual disease (MRD) in bone marrow has proven of
prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other …

… That 60% of respondents reported using MRD status to guide decision making is … on decision
making. It is also notable that the percentage of those using MRD to guide decision making …

… of residual leukemia in the bone marrow. This state has been termed minimal residual disease
(MRD)… , per Goldman and Gale, is ‘measurable residual disease’ [Citation6]. Monitoring of …

Measurable (or minimal) residual disease (MRD) in multiple myeloma (MM) refers to low
levels of myeloma cells detectable using advanced diagnostics. MRD testing is evolving, …

… residual disease monitored, can data from such studies be informative? If a threshold of
residual disease … is sustained is found, then residual disease monitoring using quantitative PCR …

In the May 1, 1999 issue of Blood, Faderl et al1 discuss the possible clinical role of polymerase
chain reaction (PCR) analysis in the surveillance of residual disease in patients with …

… The principal aim of residual disease analysis in patients … that enable the kinetics of residual
disease to be monitored over … the sensitivity with which residual disease can be excluded for …

… Measurable residual disease, as used by Short el al, 1 is … or negative for measurable residual
disease may vary by assay. … or negative in a measurable residual disease assay for AML, it …

… to make important treatment decisions in the 21st century.6, … sensitivity measurements of
residual disease burden in our … the possibility of using minimal residual disease as a surrogate …

… Relative impact of residual cytogenetic abnormalities and flow cytometric measurable
residual disease on outcome after allogeneic hematopoeitic cell transplantation in adult acute …